Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

NCT Number	NCT07008469
Lead Sponsor	Avidity Biosciences, Inc.
Conditions	Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
Enrollment	230 participants
Start Date	2025-06-26
Primary Completion	2030-08 (estimated)
Study Completion	2030-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-23